LeMaitre Vascular (NASDAQ:LMAT) issued an update on its FY18 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of $0.96-1.00 for the period, compared to the Thomson Reuters consensus estimate of $0.88. The company issued revenue guidance of $110.0-111.6 million, compared to the consensus revenue estimate of $111.26 million.LeMaitre Vascular also updated its Q1 guidance to $0.19-0.21 EPS.
LeMaitre Vascular (LMAT) traded up $0.82 on Thursday, hitting $36.33. 140,400 shares of the stock traded hands, compared to its average volume of 118,171. LeMaitre Vascular has a twelve month low of $21.36 and a twelve month high of $39.88. The company has a market capitalization of $684.10, a PE ratio of 47.39, a P/E/G ratio of 2.73 and a beta of 0.53.
LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Wednesday, February 21st. The medical instruments supplier reported $0.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.20 by $0.01. The firm had revenue of $26.15 million for the quarter, compared to analysts’ expectations of $26.23 million. LeMaitre Vascular had a net margin of 15.81% and a return on equity of 16.16%. The business’s revenue for the quarter was up 12.3% on a year-over-year basis. During the same period last year, the firm earned $0.13 earnings per share. research analysts anticipate that LeMaitre Vascular will post 0.84 EPS for the current fiscal year.
Several equities research analysts have issued reports on the stock. Zacks Investment Research upgraded shares of LeMaitre Vascular from a hold rating to a buy rating and set a $35.00 price target on the stock in a research note on Thursday, December 28th. BidaskClub downgraded shares of LeMaitre Vascular from a sell rating to a strong sell rating in a research report on Wednesday, December 27th. First Analysis downgraded shares of LeMaitre Vascular from an overweight rating to an equal weight rating and set a $34.00 target price for the company. in a report on Friday, October 27th. Canaccord Genuity dropped their price objective on shares of LeMaitre Vascular from $30.00 to $29.00 and set a hold rating for the company in a research note on Friday, October 27th. Finally, Benchmark cut shares of LeMaitre Vascular from a buy rating to a hold rating in a research note on Friday, October 27th. Six investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The company currently has an average rating of Hold and an average target price of $32.20.
COPYRIGHT VIOLATION NOTICE: “LeMaitre Vascular (LMAT) Releases FY18 Earnings Guidance” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright & trademark law. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/22/lemaitre-vascular-lmat-releases-fy18-earnings-guidance.html.
About LeMaitre Vascular
LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.